ACAD heads into its August 6 earnings report with bears in full retreat and options traders positioned firmly on the bullish side.
The most striking shift in the setup is the dramatic unwind of short positions. Short interest has fallen 23% over the past month, dropping to 6% of the float — down from a peak above 8.5% at the start of July. The unwind accelerated sharply around July 10, when short shares collapsed from roughly 14.1 million to 10.8 million in a single session. Borrow conditions tell the same story: with availability at 2,815% of outstanding short interest, there is no scarcity of shares to lend, meaning no squeeze pressure is building from the lending side. Cost to borrow remains negligible at around 0.5%, despite ticking up nearly 49% on the week — a noisy move on an already cheap rate rather than a signal of stress.
Options confirm the bullish tilt. The put/call ratio has collapsed to a near-52-week low of 0.26, well below the 20-day average of 0.28 — a reading that reflects unusually strong call-side demand relative to puts. That optimism tracks the stock itself: ACAD gained 6% on August 4 alone, and is up roughly 4% both on the week and the month, closing at $27.15.
The analyst community has been nudging its view higher in the weeks before the print. BMO Capital lifted its target to $36 and RBC Capital raised to $36 from $29 in early July — both maintaining Outperform ratings. B of A Securities, which upgraded to Buy in March, now holds a $30 target. The Street's mean target is $32.95, implying around 21% upside from current levels. Bulls focus on ACADIA's twin commercial franchises — NUPLAZID for Parkinson's disease psychosis and DAYBUE for Rett syndrome — as well as positive data from the HARMONY O45 study in the Parkinson's subgroup. Bears argue that both franchises face limited addressable populations and that DAYBUE's commercial uptake has been underwhelming, while pipeline setbacks in broader Alzheimer's disease psychosis could cap upside. EPS surprise factor scores rank in just the 12th percentile, a reminder that the company has a mixed recent history against consensus estimates.
Baker Bros. Advisors remains the anchor holder with 25% of shares, a level of specialist biotech conviction that helps explain the floor in the stock. The print will test whether DAYBUE's commercial trajectory and any pipeline updates justify the short sellers who have been covering all month — or whether the bulls who drove the stock to six-week highs went early.
See the live data behind this article on ORTEX.
Open ACAD on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
